3 High-Yield Dividend Stocks For The Next Bear Market: GlaxoSmithKline plc, Pearson plc And G4S plc

Should you buy shares in GlaxoSmithKline plc (LON:GSK), Pearson plc (LON:PSON) & G4S plc (LON:GFS) for their dividends?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When stock markets go awry, high yield stocks tend to outperform the broader market. The high-yielding dividend stocks that perform best in a downturn are so-called defensive ones. These are stocks in companies that provide goods and services always needed throughout the business cycle, enabling them to generate stable profits year after year.

Here are three high-yield stocks that could protect your portfolio in a bear market.

Controversial

GlaxoSmithKline (LSE: GSK) may be a controversial pick given its poor earnings trend. But as healthcare needs are continually rising, GSK remains a big growth opportunity. And despite recent weak results, it maintains a strong competitive position and has robust free cash flow generation.

Early signs of recovery are also beginning to show, with quarterly sales figures highlighting strong growth from its new pharmaceutical products, especially its new respiratory drug line-up including recently launched Breo, Anoro and Incruse. New products account for just £2bn in annual sales, but with continued sales growth and additional launches, sales could rise to £6bn by 2018.

Meanwhile, investors are being handsomely rewarded for their patience, with shares in the pharma giant currently yielding 5.5%. There’s one major short-term negative: with the dividend being frozen at 80p per share for 2016 and 2017, there’s no dividend growth for at least two years.

Transition

Pearson (LSE: PSON) is going through a rough patch, reporting a 2% drop in adjusted operating profits in 2015 and management giving a weak set of guidance figures for 2016. Adjusted operating profits are expected to come between £580m and £620m in 2016, which at the mid-point implies a decline of 13% on the previous year.

There are causes for optimism though. Pearson‘s competitive position is strong, and cyclical and policy factors are mainly to blame for recent weakness. This included a buoyant employment market in the US, which meant reduced college enrolment, and policy changes in the UK that lowered demand for its vocational course services.

The outlook in the longer term remains attractive. Pearson has significant exposure to growing markets in Brazil, China, India and South Africa, where it’s launching new products such as the New Student Experience. Its transition from print to digital would also likely be positive to its competitive position, given the advantage scale has on digital platforms.

With an annual dividend of 52p per share, Pearson yields 6%.

Market leader

Investor confidence in G4S (LSE: GFS) is near an all-time low, with the company seemingly embroiled in an endless list of controversies, ranging from overcharging of government contracts, human rights violations and abuse at a young offenders centre. But the company is still set to deliver strong underlying growth in revenues and earnings.

G4S remains global market leader in security services and against the backdrop of global economic uncertainty, demand for its services remains robust. In 2015, it secured new contract sales worth £2.4bn with retention rates near 90%. This shows the company has little trouble in winning new contracts even after recent scandals.

City analysts expect underlying EPS will grow 5.6% this year, to 15.2p per share. For 2017, earnings should climb another 9%, to 16.6p. This would put the shares on an attractive forward P/E of 12.2 and 11.2, respectively.

The stock’s 5.1% yield isn’t as big, but there’s potential for faster future dividend growth, given that earnings growth is set to accelerate.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »